“We are delighted to welcome Alan to our board of directors,” said Kevin A. Richardson, chairman of the board of directors of Sanuwave.
“Throughout his career, Rubino has developed a strong network of industry experts including medical device distributors. His industry knowledge and strong relationships with companies that are addressing chronic diabetes issues will be of great value to Sanuwave. We look forward to benefiting from his guidance as we work diligently to advance Sanuwave and create shareholder value.”
Rubino has served as president and chief executive officer of Emisphere Technologies, Inc. since September 2012. Previously, Rubino served as the CEO and president of New American Therapeutics, Inc., CEO and president of Akrimax Pharmaceuticals LLC and president and COO of Pharmos Corporation.
Commenting on his appointment, Rubino said, “I am most enthusiastic about joining the company’s board of directors at this time. Sanuwave represents a compelling growth opportunity with the dermaPACE Phase III clinical trial underway in the U.S. and the on-going use of the dermaPACE and orthoPACE devices outside the United States. I look forward to working with the management team to expand the international distribution of their medical devices and to develop value-enhancing strategies to compete in multiple large market opportunities.”